Viktor Drvota Email & Phone Number

Stockholm County, Sweden

Solna, Stockholm County, Se

CEO of NASDAQ listed early stage life science venture capital company. Chairman and/or BoD executive in both private and listed biotech and medtech portfolio companies.Managed convertible loan set off of 484 MSEK in 2019Managed right issue of 378 MSEK in 2022Other companies except for the companies below that I am/was indirectly involved in: Anacardio, PharmNovo, Henlez, Pharmanest/Palette.Other managed exits at KD: BioArctic, Lipidor, X Spray Pharma, Pharmanest, Asarina pharma ,ISS ,partial exits in Aprea and Ossdsign.Between 2016 to Q2 2023, KD managed portfolio companies have raised 4120 MSEK whereof KD have invested 540 MSEK. in this timeperiod KD has so far realised 435 MSEK in exit proceeds over 10 exits or partial exits and 9 companies have gone public

Solna, Stockholm County, Se

Co owned investment company by Rosetta Capital and Karolinska development.Chairman 2018, 2020 and 2022

Investment vehicle co owned by EIF (European investment fund) and Karolinska Development

Modus Therapeutics – A listed Swedish drug development company in clinical phase focused on sepsis, anemia in kidney disease and malaria.The company is entering phase IIVC round with HealtCap as lead investor in 2018IPO 2021

Umecrine Cognition is a private company developing pharmaceuticals against neurological disorders in the central nervous system, CNS that are caused by endogenous CNS-active steroids (GABA-steroids). The company is focused on the development and commercialization of novel therapeutics to treat cognitive disorders and neuroinflammation in primary biliary cholangitis (PBC) and Parkinson disease.The company have statistically significant results in phase IIa and is now conducting a phase IIb study in PBC.

Dilafor is a private pharma company developing Tafoxiparin in labour induction and preeclampsia. A phase IIb study in labor induction showed statistically significant dose response effect and the company is preparing for phase III.Several VC rounds with Rosetta capital, Östersjöstiftelsen, Praktikertjänst invest, Opocrin spa. Lee Pharamceuticals and KDAn open label study in preeclampsia is recruiting.

Uppsala, Uppsala County, Se

Medical device company developing and selling nanosythetic bone grafts and 3D implants with innovative ceramic material for cranial use.Commercial stage with distributors/ own organisation in US and EUIPO 2019. The company have raised approx. 1 bn SEK since inception in 2011Chairman 2015 11 - 2016 05

Stockholm, Stockholm, Se

Managed a university spin out from Karolinska Institute. The company is developing a curative immunotherapy for hepatitis B and D which is in preclinical stage.A Covid19 vaccine is in phase I and is being developed as PoC for the platform

Company within Womens health (endometriosis and PCOS). Several VC rounds with Novo seeds, Novartis venture fund, Vesalius, Sunstone, Merck ventures, Innovestor and KD.Sold to Organon 2021 for a total deal value of 950 MUSD

Aprea Therapeutics is a Stockholm, Sweden and Boston, Massachusetts-based biopharmaceutical company focused on the discovery and development of novel anticancer compounds In March 2016, Aprea completed a EUR 46 million Series B financing with an international syndicate co-led by Versant Ventures and 5AM Ventures, with additional participation by Sectoral Asset Management, HealthCap, acting as local lead investor, and existing investor, Karolinska Development.PreIPO round of 50 MUSD with US crossover investorsIPO NASDAQ US 2019

Medical device company developing and selling the HA Nano surface for coating of dental and orthopedic implants in order to create better osseointegration.Several deals done for example with S.I.N and Danco anodizing.Chairman 2016 07 - 2017 03IPO 2022Commercial stage

Clanotech is an ophthalmology company in preclinical phase with a lead candidate that is an inhibitor of the alpha5beta1-integrin receptor. Asset sold to Rosetta capital

The company developed commercialized a diagnostic test to differ between Chrons disease and Ulcerative colitisChairman 2013 -2016

Biotechnology company developing AKN-028, a dual mechanism inhibitor of the oncogenic FMS-like tyrosine kinase-3 (FLT3) receptor and a downstream DNA repair target for the treatment of acute myeloid leukemia (AML). Assets sold to Accelerated innovations

Solna, Stockholm County, Se

Biotechnology company developing a DNA immune modulatory drug with TLR -9 as a target in ulcerative colitis. Phase III in ulcerative colitis underwayIPO 2016 after several VC rounds with Neomed, Industrifonden and Linc

Lund, Se

A med tech company developing and selling an innovative ventilation technology for better infection control in operating theaters.Chairman 2010 11 - 2012 01 and 2012 09 . 2013 09Several VC rounds with SEB ventures and IndustrifondenCommercial stage EU

Nuevolution was a Scandinavian biopharmaceutical company focused on developing drug treatments for human diseases within oncology and chronic inflammatory diseases. Nuevolution is the inventor of Chemetics®, a patent protected drug discovery platform, which enables efficient discovery of novel small molecule (tablet based) drug candidates. The platform provides access to screening of billions of molecules and efficient optimization of drug properties in the process of identifying the drug candidate. Chemetics® has been successfully applied in numerous drug discovery and technology licensing partnerships against tough-to-drug biological disease targets, where other approaches had failed.Over the years, Nuevolution has entered 15 agreements with partners including Novartis, Janssen Biotech, Inc. (Johnson & Johnson), Boehringer Ingelheim, GlaxoSmithKline, Merck & Co (MSD), Lexicon Pharmaceuticals, as well as world-class oncology research institutions, such as Cancer Research Technology and Institute of Cancer Research.Several VC rounds with SEB ventures, Sunstone, IndustrifondenIPO in 2015 and sold to Amgen 2019 for 1,6 bSEK

Airsonett is a medtech company developing an allergen avoidance treatment for patients with severe atopic asthma who, in spite of taking asthma medication, still has poorly controlled asthma.Airsonett ensures that the patient sleeps in clean air. Studies show that Airsonett inhibits the allergy, reduces the inflammation and improves quality of life. Several pivotal studies performed before commercialization.Several VC rounds with SEB venture and IndustrifondenCommercial stage EU

SciBase AB is a Swedish medical technology company, headquartered in Stockholm, that has developed a unique point of care device for the accurate detection of malignant melanoma, Keranocyte cancers and skin barrier defects. The technology is based on electrical impedance in combination with AI.The company have done a PMA In USCommercial stage EU and USIPO in 2015 after several VC rounds with SEB venture and Fourrier TransformChairman 2014 01 - 2014 04

Stockholm, Stockholm, Se

Portfolio responsibility for life science portfolio at SEB venture capital with 240 M€ in an evergreen fund structure. in 2016, SEB VC have done101 investments and 71 exits since it´s inception in 1995.Multiple investments done / negotiated both in medtech and pharma companies. Large experience from board work in VC backed companies.The companies I was involved in during this time period raised more than 2 billion SEKOther companies except for the companies below that I was involved in: Cresco SA (sold to Astra Tech), Prostalund (sold back to founders), Personal chemistry (Biotage)(IPO Stockholm), LightUp AB (merged with Bactus AB) , X-counter (IPO Aim London), Also serving in the investment commitee of the IT/tech venture part of SEB VCAs part of the management team at SEB VC since 2005 I have been indirectly involved in the following tech Exits among others:Kreatel AB, trade sale to Motorola Inc 2006; Interpeak AB trade sale to Windriver Inc 2006; Carmen systems, trade sale to Boeing Inc 2006; Spotfire Inc, trade sale to Tibco Inc 2007; Zealcore AB, trade sale to Enea AB 2008; TimeCare AB, trade sale to Allocate software 2009, 3Nine AB, trade sale to Sagri development AB 2010; Ascade holding AB trade sale to CSG International 2012, Tail-F to Cisco 2014.

Mölndal, Se

Neoventa is a medical device company developing a fetal monitoring device. Performed several large (5000 + patients) clinical studies before commercialization.Several VC rounds with Investor growth capital, HealthCap and SEB venturesPMA in US doneCommercial stage EU

Quickcool devloped an intranasal cooling device for cardiac arrest patientsSeveral VC rounds with CapMan and SEB ventureSold back to founders

Developed a GLP-2 agonist for Osteoporosis through phase II. Several VC rounds with SLS venture and SEB ventureSold to Nordic Biotech A/S

Vaccine company with a proprietary vaccin for Cholera and a major vaccin distributor in Scandinavia. Management buy out with 3i and SEB ventureSold to Crucell in 2006

Medical device company developing sensors anestethic gases as well as Oxygen and CO2.Sold to Masimo Inc

Research tool company within oligonucleotide synthesis, DNA micro arrays, in vitro diagnostics and molecular analysis. Several VC rounds with Industrifonden and SLS venturesSold back to founder sin 2006

Pharmaceutical company who developed a drug for fat malabsorption in CF and neonates through phase II. Several VC rounds with 3i, Industrifonden and SEB venturesSold to SOBI in 2005

- Associate professor of cardiology (interventional cardiologist) / Senior consultant- 33 Published articles in peer reviewed journals with a mean impact factor of 3.9 (1.2 - 29.5)- Tutored three PhD students- PhD thesis 1997: Molecular Pharmacology of Amiodarone (research in an industry collaboration with pharmaceutical company KaroBio focusing on thyroid hormone receptor as an antiarrhythmic concept)- Together with Prof. Christer Sylvén responsible for (and founded) the Cardiac Molecular Laboratory at NOVUM research center, Karolinska Institute 1996 – 2002. We focused on gene therapy with VEGF in refractory angina pectoris patients (part of multinational placebo controlled trial, Euroinject) and stemcell therapies.- Extensive academic teaching experience

Doctor Of Medicine (M.D.), Medicine

Business And Administration

Associate Professor, Cardiology

Specialist, Interventional Cardiology Residency Program

Doctor Of Philosophy - Phd, Internal Medicine

Doctor Of Medicine - Md